These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again! Wooten DJ; Quaranta V Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217 [TBL] [Abstract][Full Text] [Related]
5. A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. Stanta G; Bonin S Pathobiology; 2018; 85(1-2):7-17. PubMed ID: 28750401 [TBL] [Abstract][Full Text] [Related]
6. Changing mutational and adaptive landscapes and the genesis of cancer. Liggett LA; DeGregori J Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050 [TBL] [Abstract][Full Text] [Related]
7. Intratumor Heterogeneity in Breast Cancer. Beca F; Polyak K Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535 [TBL] [Abstract][Full Text] [Related]
8. Cancer Plasticity: The Role of mRNA Translation. Lee LJ; Papadopoli D; Jewer M; Del Rincon S; Topisirovic I; Lawrence MG; Postovit LM Trends Cancer; 2021 Feb; 7(2):134-145. PubMed ID: 33067172 [TBL] [Abstract][Full Text] [Related]
9. Clinical implications of intratumor heterogeneity: challenges and opportunities. Ramón Y Cajal S; Sesé M; Capdevila C; Aasen T; De Mattos-Arruda L; Diaz-Cano SJ; Hernández-Losa J; Castellví J J Mol Med (Berl); 2020 Feb; 98(2):161-177. PubMed ID: 31970428 [TBL] [Abstract][Full Text] [Related]
11. Evolution of phenotypic plasticity leads to tumor heterogeneity with implications for therapy. Syga S; Jain HP; Krellner M; Hatzikirou H; Deutsch A PLoS Comput Biol; 2024 Aug; 20(8):e1012003. PubMed ID: 39121170 [TBL] [Abstract][Full Text] [Related]
12. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Marusyk A; Janiszewska M; Polyak K Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271 [TBL] [Abstract][Full Text] [Related]
13. Rare Mutations in Cancer Drug Resistance and Implications for Therapy. Beckman RA; Loeb LA Clin Pharmacol Ther; 2020 Sep; 108(3):437-439. PubMed ID: 32648584 [No Abstract] [Full Text] [Related]
14. Hypoxia-driven intratumor heterogeneity and immune evasion. Terry S; Engelsen AST; Buart S; Elsayed WS; Venkatesh GH; Chouaib S Cancer Lett; 2020 Nov; 492():1-10. PubMed ID: 32712233 [TBL] [Abstract][Full Text] [Related]
15. New insights from the widening homogeneity perspective to target intratumor heterogeneity. Tong M; Deng Z; Zhang X; He B; Yang M; Cheng W; Liu Q Cancer Commun (Lond); 2018 May; 38(1):17. PubMed ID: 29764517 [TBL] [Abstract][Full Text] [Related]
16. Cancer plasticity in therapy resistance: Mechanisms and novel strategies. Niu X; Liu W; Zhang Y; Liu J; Zhang J; Li B; Qiu Y; Zhao P; Wang Z; Wang Z Drug Resist Updat; 2024 Sep; 76():101114. PubMed ID: 38924995 [TBL] [Abstract][Full Text] [Related]
17. Variability in the Solid Cancer Cell Population and Its Consequences for Cancer Diagnostics and Treatment. Brychtová V; Valík V; Vojtěšek B Klin Onkol; 2018; 31(Suppl 2):5-13. PubMed ID: 31023018 [TBL] [Abstract][Full Text] [Related]
19. Intratumor heterogeneity: evolution through space and time. Swanton C Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210 [TBL] [Abstract][Full Text] [Related]
20. Intratumor heterogeneity in epigenetic patterns. Assenov Y; Brocks D; Gerhäuser C Semin Cancer Biol; 2018 Aug; 51():12-21. PubMed ID: 29366906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]